NCT01070914

Brief Summary

Primary Ciliary Dyskinesia (PCD) is a severe genetic disorder caused by various mutations in genes affecting ciliary motility. Various new and complementary diagnostic techniques, including measurements of nasal nitric oxide (NO), Video Microscopy (VM), Immunoflourescence (IF) and genetic analysis have recently been recognized as simpler and more accurate modalities for the diagnosis and characterization of patients with PCD compared to electron microscopy. While considered a rare disease worldwide, PCD is more prevalent among highly consanguineous populations, such as those found in Israel. We hypothesize that using modern state of the art and novel test modalities on a national scale in Israel will improve diagnosis, improve phenotypic-genotypic correlations and create a national registry for PCD.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
130

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2011

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 6, 2010

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 18, 2010

Completed
1.3 years until next milestone

Study Start

First participant enrolled

June 1, 2011

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

May 8, 2012

Status Verified

May 1, 2012

Enrollment Period

1.5 years

First QC Date

February 6, 2010

Last Update Submit

May 7, 2012

Conditions

Keywords

CiliaPhenotypingDiagnosisNitric OxideBronchiectasis

Outcome Measures

Primary Outcomes (1)

  • Phenotypic and genetic characterization

    2 years

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Residents of Israel

You may qualify if:

  • Patients with PCD diagnosis
  • Subjects with suspected diagnosis of PCD

You may not qualify if:

  • Subjects Uncooperative with study procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ziv Medical center

Safed, 13100, Israel

RECRUITING

Related Publications (1)

  • Amirav I, Mussaffi H, Roth Y, Schmidts M, Omran H, Werner C; Israeli PCD Consortium Investigators. A reach-out system for video microscopy analysis of ciliary motions aiding PCD diagnosis. BMC Res Notes. 2015 Mar 8;8:71. doi: 10.1186/s13104-015-0999-x.

MeSH Terms

Conditions

Ciliary Motility DisordersDiseaseBronchiectasis

Condition Hierarchy (Ancestors)

Respiratory Tract DiseasesOtorhinolaryngologic DiseasesCiliopathiesAbnormalities, MultipleCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGenetic Diseases, InbornPathologic ProcessesPathological Conditions, Signs and SymptomsBronchial Diseases

Study Officials

  • Israel Amirav, MD

    Ziv Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Israel Amirav, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 6, 2010

First Posted

February 18, 2010

Study Start

June 1, 2011

Primary Completion

December 1, 2012

Study Completion

June 1, 2013

Last Updated

May 8, 2012

Record last verified: 2012-05

Locations